ATC Abstracts

American Transplant Congress abstracts

2017 American Transplant Congress » Concurrent Session: Treatment of Antibody Mediated Rejection in Kidney Transplant Recipients

Date: Monday, May 1, 2017

Time: 2:30pm-4:00pm

Location: E354a

Session Type: Concurrent Session

Meeting: 2017 American Transplant Congress

2:30pm-2:42pm
Saftey & Long Term Outcomes of Tocilizumab (Anti-IL6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly-HLA Sensitized (HS) Patients (PTs).

J. Choi,1 O. Aubert,2 A. Vo,1 A. Loupy,2 M. Haas,3 S. Louie,1 A. Kang,1 A. Peng,1 R. Najjar,1 E. Huang,1 M. Toyota,5 X. Zhang,4 S. Jordan.1

2:42pm-2:54pm
Composite Prognostic Score Improves Clinical Benefit in Kidney Recipients Receiving Standard of Care Therapy for Antibody-Mediated Rejection.

D. Viglietti, A. Loupy, O. Aubert, E. Pillebout, C. Legendre, D. Glotz, C. Lefaucheur.

2:54pm-3:06pm
Complement Activating Anti-HLA Antibodies: Identification of Specific Histo-Mmolecular Phenotype of Rejection for Complement-Targeting Therapy.

C. Lefaucheur,1 B. Sis,2 D. Viglietti,1 L. Hidalgo,2 O. Aubert,1 D. Glotz,1 C. Legendre,1 A. Zeevi,3 P. Halloran,2 A. Loupy.1

3:06pm-3:18pm
Safety and Activity of Anti-C1s Humanized Monoclonal Antibody TNT009 in Late Antibody-Mediated Kidney Allograft Rejection – Results of a First-in-Human Phase 1 Trial.

F. Eskandary,1 B. Jilma,2 J. Muehlbacher,3 M. Wahrmann,1 H. Regele,4 N. Kozakowski,4 S. Panicker,5 J. Reeve,6 P. Halloran,6 J. Gilbert,5 G. Bohmig.1

3:18pm-3:30pm
Experience with Obinutuzumab (Type II Anti-CD20) in Kidney Transplant Patients with Donor Specific Antibody (DSA+) Antibody Mediated Rejection.

J. Choi, A. Vo, E. Huang, S. Louie, A. Kang, A. Peng, R. Najjar, S. Jordan.

3:30pm-3:42pm
Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation.

D. Kumar,1 G. Gupta,1 J. Reeve,2 P. Sanghi,1 S. Bobba,1 M. Levy,1 C. Bhati,1 P. Kimball,1 H. Fattah,1 A. King,1 H. Massey,1 P. Halloran.2

3:42pm-3:54pm
Rapid Depletion of Circulating DSA and Treatment of Acute Antibody-Mediated Rejection with the Combination of CTLA-4Ig/Belatacept and Bortezomib in Mouse and Man.

J. Young,1 A. Vannier,1 G. Bumgardner,2 A. Chong,1 R. Pelletier.2

« View all sessions from the 2017 American Transplant Congress